Myomo (MYO) Cash from Financing Activities (2016 - 2025)
Myomo (MYO) posted Cash from Financing Activities of -$50000.0 for Q3 2025, down 101.25% on a QoQ basis from $4.0 million in Q2 2025, and up 74.94% year-over-year from -$28581.7 in Q3 2024.
Myomo (MYO) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Myomo's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$50000.0 for Q3 2025.
- Quarterly Cash from Financing Activities rose 74.94% year-over-year to -$50000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $19.7 million (up 281.28% YoY) and the FY2024 annual result came in at $20.9 million, up 115.5% from the prior year.
- Cash from Financing Activities was -$50000.0 for Q3 2025 at Myomo, down from $4.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.8 million in Q4 2024 and bottomed at -$199500.0 in Q3 2024.
- A 5-year average of $3.2 million and a median of $1.1 million in 2021 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 50870932.26% in 2024, while the deepest fall reached 105.05% in 2024.
- Myomo's Cash from Financing Activities stood at $4.8 million in 2021, then slumped by 92.12% to $376858.0 in 2022, then slumped by 99.99% to $31.0 in 2023, then surged by 50870932.26% to $15.8 million in 2024, then slumped by 100.32% to -$50000.0 in 2025.
- Business Quant data shows MYO's Cash from Financing Activities at -$50000.0 in Q3 2025, $4.0 million in Q2 2025, and -$36506.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Myomo | 39.24 Mn | 20.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -50,000.00 |
| Sep 30, 2025 | -50,000.00 |
| Jun 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 4.00 Mn |
| Mar 31, 2025 | -36,506.00 |
| Mar 31, 2025 | -36,506.00 |
| Dec 31, 2024 | 15.77 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Sep 30, 2024 | -199,500.00 |
| Sep 30, 2024 | -199,500.00 |
| Mar 31, 2024 | 5.36 Mn |
| Mar 31, 2024 | 5.36 Mn |
| Dec 31, 2023 | 31.00 |
| Dec 31, 2023 | 31.00 |
| Sep 30, 2023 | 3.95 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | -8,147.00 |
| Jun 30, 2023 | -8,147.00 |
| Mar 31, 2023 | 5.77 Mn |
| Mar 31, 2023 | 5.77 Mn |